National Health and Medical Research Council

Entity resources and planned performance

# National Health and Medical Research Council

[Section 1: Entity overview and resources 378](#_Toc166421863)

[1.1 Strategic direction statement 378](#_Toc166421864)

[1.2 Entity resource statement 379](#_Toc166421865)

[1.3 Budget measures 381](#_Toc166421866)

[Section 2: Outcomes and planned performance 382](#_Toc166421867)

[2.1 Budgeted expenses and performance for Outcome 1 382](#_Toc166421868)

[Section 3: Budgeted financial statements 389](#_Toc166421869)

[3.1 Budgeted financial statements 389](#_Toc166421870)

[3.2. Budgeted financial statements tables 390](#_Toc166421871)

# National Health and Medical Research Council

## Section 1: Entity overview and resources

### 1.1 Strategic direction statement[[1]](#footnote-2)

The National Health and Medical Research Council (NHMRC) is the Australian Government’s key entity for managing investment in health and medical research. NHMRC is also responsible for developing evidence-based health advice for the Australian community, health professionals and governments, and for promoting the highest standards of ethics and integrity in health and medical research.

NHMRC continues to support high quality research through its grant program, which encourages innovation in research and provides opportunities for talented researchers at all career stages. This work is facilitated by NHMRC’s modern grants management solution, Sapphire, which has streamlined the application, peer review assessment and grant management processes.

NHMRC continues to support the Department of Health and Aged Care with the delivery of the Medical Research Future Fund (MRFF) grant opportunities. NHMRC and the Department are also progressing work to improve alignment and coordination between the MRFF and NHMRC’s grant program, delivered through the Medical Research Endowment Account (MREA), as well as commencing work together towards the Department’s delivery of a National Strategy for Health and Medical Research.

NHMRC’s work also facilitates and promotes the translation of evidence from health and medical research into practices, policies and products designed to prevent and treat illness and improve the health of the Australian community. NHMRC’s guidelines and advice support states and territories in achieving consistent standards in public and environmental health.

The role and functions of NHMRC are set out in the *National Health and Medical Research Council Act 1992*. NHMRC also has statutory obligations under the *Prohibition of Human Cloning for Reproduction Act 2002,* the *Research Involving Human Embryos Act 2002*, and the *Medical Research Future Fund Act 2015*. NHMRC is a non‑corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity resource statement

Table 1.1 shows the total resourcing from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, please refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‘Budgeted expenses by Outcome 1’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis. Amounts presented below are consistent with amounts presented in the Appropriation Bills themselves.

Table 1.1: NHMRC resource statement – Budget estimates for 2024–25 as at Budget May 2024

|  |  |  |
| --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Estimate  $'000** |
| **DEPARTMENTAL** |  |  |
| Prior year appropriation available | 349 | 349 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 46,414 | 38,248 |
| s74 retained revenue receipts (b) | 13,100 | 12,620 |
| Departmental Capital Budget (c) | 185 | 190 |
| Other services (d) |  |  |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **59,699** | **51,058** |
| **Total departmental resourcing for NHMRC** | **60,048** | **51,407** |

**Table 1.1: NHMRC resource statement – Budget estimates for 2024–25 as at Budget May 2024 (continued)**

|  |  |  |
| --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Estimate  $'000** |
| **ADMINISTERED** |  |  |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Outcome 1 | 923,780 | 953,872 |
| Other services (d) |  |  |
| Administered assets and liabilities | - | - |
| **Total administered annual appropriations** | **923,780** | **953,872** |
| **Special accounts (e)** |  |  |
| Opening balance | 329,746 | 304,518 |
| Appropriation receipts | 910,652 | 940,330 |
| Appropriation receipts - other entities (f) | - | - |
| Non-appropriation receipts | 10,000 | 10,000 |
| **Total special accounts** | **1,250,398** | **1,254,848** |
| **Total administered resourcing** | **2,174,178** | **2,208,720** |
| Less appropriations drawn from annual or special appropriations above and credited to special accounts (g) | (910,652) | (940,330) |
| **Total administered resourcing** | **1,263,526** | **1,268,390** |
| **Total resourcing for NHMRC** | **1,323,574** | **1,319,797** |
|  |  |  |
|  | **2023–24** | **2024–25** |
| **Average staffing level (number)** | 205 | 205 |

All figures are GST exclusive.

(a) Appropriation Bill (No.1) 2024–25.

(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No.1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) Appropriation Bill (No.2) 2024–25.

(e) For further information on special appropriations and special accounts, please refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1 within this chapter for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

(f) Appropriation receipts from the Department of Health and Aged Care.

(g) Appropriation receipts included above.

### 1.3 Budget measures

Budget measures in Part 1 relating to the NHMRC are detailed in Budget Paper No. 2 and are summarised below.

Table 1.2: NHMRC 2024–25 Budget measures

**Part 1: Measures announced since the 2023–24 Mid-Year Economic and Fiscal Outlook (MYEFO)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Program** | | **2023–24 $'000** | | **2024–25 $'000** | **2025–26 $'000** | **2026–27 $'000** | **2027–28 $'000** |
| **Portfolio Administrative Matters (a)** | |
| National Health and Medical Research Council | | | | |  |  |  |  |
| Departmental payments | 1.1 | | 9,000 | | - | - | - | - |
| **Total payments** |  | | 9,000 | | **-** | **-** | **-** | **-** |
| **Savings from External Labour ‐ extension (a)** | | | |
| National Health and Medical Research Council | | | | |  |  |  |  |
| Departmental payments | 1.1 | | - | | (102) | (112) | (114) | (827) |
| **Total payments** |  | | - | | **(102)** | **(112)** | **(114)** | **(827)** |

(a) NHMRC is not the lead entity for this measure. NHMRC impacts only are shown in this table.

## Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

|  |
| --- |
| **Note:**  Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measure described in Portfolio Budget Statements will be read with broader information provided in an entity’s corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity’s planned and actual performance.  The most recent Corporate Plan and Annual Performance Statements for the NHMRC can be found at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports |

### 2.1 Budgeted expenses and performance for Outcome 1

|  |
| --- |
| Outcome 1  Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health. |

**Program contributing to Outcome 1**

|  |
| --- |
| **Program 1.1: Health and Medical Research** |

**Linked Programs**

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health and Aged Care |
| Program 1.1: Health Research, Coordination and Access  Program 1.8: Health Protection, Emergency Response and Regulation  The Department of Health and Aged Care contributes to health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future, and drive further medical innovation (1.1).  The Department of Health and Aged Care contributes to the promotion of public health through the Chief Medical Officer and the Office of Health Protection and Response, which coordinates national health protection policy and response (1.8). |

##### Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **Program 1.1: Health and Medical Research** | |
| Administered expenses |  | |  |  |  |  |
| Ordinary annual services (a) | 923,780 | | 953,872 | 974,889 | 993,785 | 1,013,661 |
| to Medical Research Endowment Account | (910,652) | | (940,330) | (961,099) | (979,749) | (999,346) |
| Special accounts |  | |  |  |  |  |
| Medical Research Endowment Account | 945,880 | | 984,155 | 1,001,508 | 999,772 | 1,030,243 |
| Departmental expenses |  | |  |  |  |  |
| Departmental appropriation (b) | 57,149 | | 48,384 | 48,899 | 49,617 | 49,332 |
| Expenses not requiring appropriation in the Budget year (c) | 5,717 | | 5,682 | 5,408 | 5,323 | 5,207 |
| Operating deficit (surplus) | - | | - | - | - | - |
| **Total for Program 1.1** | **1,021,874** | | **1,051,763** | **1,069,605** | **1,068,748** | **1,099,097** |
| **Total expenses for Outcome 1** | **1,021,874** | | **1,051,763** | **1,069,605** | **1,068,748** | **1,099,097** |
|  |  | |  |  |  |  |
|  | **2023–24** | | **2024–25** |  |  |  |
| **Average staffing level (number)** | 205 | | 205 |  |  |  |

(a) Appropriation Bill (No.1) 2024–25.

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No.1) and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It is used by entities to describe the results they plan to achieve and the related key activities, as detailed in the current corporate plan, the context in which these activities are delivered, and how the performance of these activities will be measured. Where relevant, details of the 2024–25 Budget measures that have created new programs or materially changed existing programs are provided.

**Table 2.1.2: Performance measures for Outcome 1**

|  |  |
| --- | --- |
| **Outcome 1**  Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health. | |
| **Program 1.1: Health and Medical Research**  The Australian Government, through NHMRC, aims to:   * create knowledge and build research capability through investment in the highest quality health and medical research, and the best researchers (Investment) * drive the translation of health and medical research into public policy, health systems and clinical practice, and support the commercialisation of research discoveries (Translation) * maintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust (Integrity). | |
| **Key Activities** | * Investment: * fund the best researchers and research to meet Australia’s diverse health and medical research needs, and invest in innovative and collaborative research projects * fund research to improve health outcomes for First Nations Australians, and build and strengthen Aboriginal and Torres Strait Islander health researcher capacity. * Translation: * develop and update guidelines in public and environmental health and clinical practice to support consistent standards and clinical, policy and regulatory decisions * drive translation of evidence into innovative and evidence-based health care and public health policy. * Integrity: * promote the highest standards of research quality and integrity, including engaging with the research sector on good practice and maintaining key statements, codes and human research and ethics guidelines * administer the *Research Involving Human Embryos Act 2002* and the *Prohibition of Human Cloning for Reproduction Act 2002*, as amended by the *Mitochondrial Donation Law Reform (Maeve’s Law) Act 2022*, through the work of the Embryo Research Licensing Committee. |

|  |  |  |
| --- | --- | --- |
| **Program 1.1: Health and Medical Research** | | |
| **Year** | **Performance Measure** | **Expected Performance Results** |
| Current Year 2023–24 | Research grants in basic science, clinical medicine, public health and health services research meet the health needs of Australians, and include national, state and territory and community priorities. | Grants were awarded based on expert peer review across the full spectrum of health and medical research areas, and focus on achieving better health outcomes[[2]](#footnote-3).  More than 5% of NHMRC’s annual research grant budget was expended and awarded on research that will provide better health outcomes for Aboriginal and Torres Strait Islander people. |
| **Year** | **Performance Measure** | **Planned Performance Results** |
| Budget Year 2024–25 | As per 2023–24 | Grants are awarded based on expert peer review across the full spectrum of health and medical research areas, and focus on achieving better health outcomes[[3]](#footnote-4).  More than 5% of NHMRC’s annual research grant budget is expended/awarded on research that will provide better health outcomes for Aboriginal and Torres Strait Islander people. |
| Forward Estimates 2025–28 | As per 2024–25 | As per 2024–25 |

|  |  |  |
| --- | --- | --- |
| **Program 1.1: Health and Medical Research** | | |
| **Year** | **Performance Measure** | **Expected Performance Results** |
| Current Year 2023–24 | Support an Australian health system that is research-led, evidence-based, efficient and sustainable. | NHMRC has approved or expects to approve the following clinical practice guidelines developed by third parties:   * National Guideline for the Assessment and Diagnosis of Autism in Australia 2023 * Updates to the Australian Evidence-Based Clinical Guidelines for Diabetes * Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer: Population Screening and Risk and Screening Based on Family History * International Evidence Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023 * Update to the Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis * Australian Immunisation Handbook – Human Papillomavirus Chapter * Update to the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis * New and updated recommendations for the Australian Guidelines for the Care of People with COVID-19 * Society of Obstetric Medicine Australia and New Zealand Guideline for the Management of Hypertensive Disorders of Pregnancy 2023 * Guidelines for Care Around Stillbirth and Neonatal Death * Updates to the Clinical Guidelines for Stroke Management * Australian Clinical Guideline for Physical Rehabilitation and Mobilisation in Adult Intensive Care Units * Update to the Australian Pregnancy Care Guidelines (on track) * Australian Postnatal Care Guidelines (on track) * Australian Immunisation Handbook – mpox Chapter (on track) * Australian Physical Activity Clinical Practice Guideline for People with Moderate to Severe Traumatic Brain Injury (on track) * Australian Evidence-Based Guideline for unexplained infertility (on track) * Guideline for Growth, Health and Developmental Follow-Up for Children Born Very Preterm (on track) * Fetal Alcohol Spectrum Disorder guidelines (on track).   NHMRC has developed and/or is developing the following public and environmental health guidelines:   * Review of 2013 *Australian Dietary Guidelines* (in progress) * Evidence evaluations of 16 natural therapies excluded from private health insurance rebates on 1 April 2019 (excluded natural therapies) (in progress) * Nutrient Reference Values (NRVs) for Australia and New Zealand – priority rolling review 2006 NRVs (Sodium, Iodine and Selenium in progress) * *Australian Drinking Water Guidelines –* consequential edits resulting from publication of microbial health-based targets (to be published March 2024) * *Australian drinking water guidelines*: public health advice for lead substitutes in plumbing products (in progress) * *Australian Drinking Water Guidelines*: review of existing PFAS guideline values (in progress) * Review of *Guidelines for Managing Risks from Recreational  Water* (in progress) * Staying Healthy: Preventing Infectious Diseases in Early Childhood Education and Care Services (6th Edition)  (in progress). |
| **Year** | **Performance Measure** | **Planned Performance Results** |
| Budget Year 2024–25 | As per 2023–24 | Develop and/or approve public and environmental health and clinical practice guidelines. |
| Forward Estimates 2025–28 | As per 2024–25 | As per 2024–25 |

|  |  |  |
| --- | --- | --- |
| **Program 1.1: Health and Medical Research** | | |
| **Year** | **Performance Measure** | **Expected Performance Results** |
| Current Year 2023–24 | Research is conducted responsibly, ethically and with integrity in Australia. | Research integrity matters were managed appropriately by administering institutions in line with the requirements of the *Australian Code for the Responsible Conduct of Research*.[[4]](#footnote-5) |
| **Year** | **Performance Measure** | **Planned Performance Results** |
| Budget Year 2024–25 | As per 2023–24 | Research integrity matters are managed appropriately by administering institutions in line with the requirements of the *Australian Code for the Responsible Conduct of Research*. |
| Forward Estimates 2025–28 | As per 2024–25 | As per 2024–25 |
| Material changes to Program 1.1 resulting from 2024–25 Budget Measures: Nil | | |

## Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2024–25 Budget year, including the impact of budget measures and resourcing on financial statements.

### 3.1 Budgeted financial statements

#### 3.1.1 Differences between entity resourcing and financial statements

This section is not applicable to NHMRC.

#### 3.1.2 Explanatory notes and analysis of budgeted financial statements

**Departmental Resources**

**Comprehensive Income Statement (showing net cost of services)**

Revenue and expenditure for 2024–25 is expected to be in line with Government forecasts, with employee expenses to be 57% of total expenditure.

**Balance Sheet**

Assets and Liabilities are expected to remain stable across the Budget and forward years.

**Administered Resources**

The Administered accounts are used as a mechanism to transfer the majority of funds to NHMRC’s Special Account (Medical Research Endowment Account). In 2024–25 the transfer to the Special Account is expected to be $940 million.

### 3.2. Budgeted financial statements tables

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **EXPENSES** |  |  |  |  |  |
| Employee benefits | 29,439 | 30,557 | 31,596 | 32,608 | 33,585 |
| Supplier expenses | 27,453 | 17,598 | 17,103 | 16,840 | 15,609 |
| Depreciation and amortisation | 5,825 | 5,790 | 5,516 | 5,431 | 5,315 |
| Interest on RoU | 149 | 121 | 92 | 61 | 30 |
| Other | - | - | - | - | - |
| **Total expenses** | **62,866** | **54,066** | **54,307** | **54,940** | **54,539** |
| **LESS:** |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | 13,100 | 12,620 | 12,620 | 12,620 | 12,620 |
| **Total revenue** | **13,100** | **12,620** | **12,620** | **12,620** | **12,620** |
| **Gains** |  |  |  |  |  |
| Other | 108 | 108 | 108 | 108 | 108 |
| **Total gains** | **108** | **108** | **108** | **108** | **108** |
| **Total own-source income** | **13,208** | **12,728** | **12,728** | **12,728** | **12,728** |
| **Net cost of (contribution by) services** | **49,658** | **41,338** | **41,579** | **42,212** | **41,811** |
| Revenue from Government | 46,414 | 38,248 | 38,813 | 39,581 | 39,296 |
| **Surplus (deficit)** | **(3,244)** | **(3,090)** | **(2,766)** | **(2,631)** | **(2,515)** |
| **Surplus (deficit) attributable to the Australian Government** | **(3,244)** | **(3,090)** | **(2,766)** | **(2,631)** | **(2,515)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income (loss)** | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(3,244)** | **(3,090)** | **(2,766)** | **(2,631)** | **(2,515)** |

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Note: Impact of net cash appropriation arrangements** | | | | | |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** | |
| **Total comprehensive income  (loss) attributable to the  Australian Government** | **(3,244)** | **(3,090)** | **(2,766)** | **(2,631)** | **(2,515)** | |
| plus non-appropriated expenses depreciation and amortisation expenses | 3,077 | 3,220 | 3,084 | 2,999 | 2,883 | |
| plus depreciation and amortisation expenses for RoU | 2,748 | 2,570 | 2,432 | 2,432 | 2,432 | |
| less lease principal repayments | (2,581) | (2,700) | (2,750) | (2,800) | (2,800) | |
| **Total comprehensive income (loss) attributable to the agency** | **-** | **-** | **-** | **-** | **-** | |

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **ASSETS** |  |  |  |  |  |
| **Financial assets** |  |  |  |  |  |
| Cash and cash equivalents | 349 | 349 | 349 | 349 | 349 |
| Receivables | 617 | 617 | 617 | 617 | 617 |
| **Total financial assets** | **966** | **966** | **966** | **966** | **966** |
| **Non-financial assets** |  |  |  |  |  |
| Property, plant and equipment | 1,957 | 1,546 | 1,181 | 889 | 709 |
| Land and buildings | 10,868 | 8,310 | 5,878 | 3,446 | 1,014 |
| Inventories | 54 | 54 | 54 | 54 | 54 |
| Intangibles | 22,533 | 19,902 | 17,375 | 14,862 | 12,354 |
| Other | 2,137 | 2,137 | 2,137 | 2,137 | 2,137 |
| **Total non-financial assets** | **37,549** | **31,949** | **26,625** | **21,388** | **16,268** |
| **Total assets** | **38,515** | **32,915** | **27,591** | **22,354** | **17,234** |
| **LIABILITIES** |  |  |  |  |  |
| **Payables** |  |  |  |  |  |
| Suppliers | 4,415 | 4,415 | 4,415 | 4,415 | 4,415 |
| Other payables | 3,015 | 3,015 | 3,015 | 3,015 | 3,015 |
| **Total payables** | **7,430** | **7,430** | **7,430** | **7,430** | **7,430** |
| **Interest bearing liabilities** |  |  |  |  |  |
| Leases | 12,224 | 9,524 | 6,774 | 3,974 | 1,174 |
| **Total interest bearing liabilities** | **12,224** | **9,524** | **6,774** | **3,974** | **1,174** |
| **Provisions** |  |  |  |  |  |
| Employees | 7,557 | 7,557 | 7,557 | 7,557 | 7,557 |
| **Total provisions** | **7,557** | **7,557** | **7,557** | **7,557** | **7,557** |
| **Total liabilities** | **27,211** | **24,511** | **21,761** | **18,961** | **16,161** |
| **Net Assets** | **11,304** | **8,404** | **5,830** | **3,393** | **1,073** |
| **EQUITY** |  |  |  |  |  |
| Contributed equity | 17,386 | 17,576 | 17,768 | 17,962 | 18,157 |
| Reserves | 1,367 | 1,367 | 1,367 | 1,367 | 1,367 |
| Retained surpluses or (accumulated deficits) | (7,449) | (10,539) | (13,305) | (15,936) | (18,451) |
| **Total equity** | **11,304** | **8,404** | **5,830** | **3,393** | **1,073** |

Prepared on Australian Accounting Standards basis.

Table 3.3: Departmental statement of changes in equity – summary of movement (Budget year 2024–25)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings   $'000** | **Asset revaluation reserve  $'000** | **Contributed equity/ capital  $'000** | **Total  equity   $'000** |
| **Opening balance as at 1 July 2024** |  |  |  |  |
| Balance carried forward from previous period | (7,449) | 1,367 | 17,386 | **11,304** |
| Surplus (deficit) for the period | (3,090) | - | - | **(3,090)** |
| Capital budget - Bill 1 (DCB) | - | - | 190 | **190** |
| **Estimated closing balance as at  30 June 2025** | **(10,539)** | **1,367** | **17,576** | **8,404** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **OPERATING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Goods and services | 13,100 | 12,620 | 12,620 | 12,620 | 12,620 |
| Appropriations | 46,414 | 38,248 | 38,813 | 39,581 | 39,296 |
| Net GST received | - | - | - | - | - |
| **Total cash received** | **59,514** | **50,868** | **51,433** | **52,201** | **51,916** |
| **Cash used** |  |  |  |  |  |
| Employees | 29,439 | 30,557 | 31,596 | 32,608 | 33,585 |
| Suppliers | 27,345 | 17,490 | 16,995 | 16,732 | 15,501 |
| Cash to the OPA | - | - | - | - | - |
| Interest payments on lease liability | 149 | 121 | 92 | 61 | 30 |
| **Total cash used** | **56,933** | **48,168** | **48,683** | **49,401** | **49,116** |
| **Net cash from (or used by) operating activities** | **2,581** | **2,700** | **2,750** | **2,800** | **2,800** |
| **INVESTING ACTIVITIES** |  |  |  |  |  |
| **Cash used** |  |  |  |  |  |
| Purchase of property, plant and equipment | 185 | 190 | 192 | 194 | 195 |
| **Total cash used** | **185** | **190** | **192** | **194** | **195** |
| **Net cash from (or used by) investing activities** | **(185)** | **(190)** | **(192)** | **(194)** | **(195)** |
| **FINANCING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Equity injections - Bill 2 | - | - | - | - | - |
| Capital budget - Bill 1 (DCB) | 185 | 190 | 192 | 194 | 195 |
| **Total cash received** | **185** | **190** | **192** | **194** | **195** |
| **Cash used** |  |  |  |  |  |
| Lease principal repayments | 2,581 | 2,700 | 2,750 | 2,800 | 2,800 |
| **Total cash used** | **2,581** | **2,700** | **2,750** | **2,800** | **2,800** |
| **Net cash from (or used by) financing activities** | **(2,396)** | **(2,510)** | **(2,558)** | **(2,606)** | **(2,605)** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 349 | 349 | 349 | 349 | 349 |
| **Cash and cash equivalents at the end of the reporting period** | **349** | **349** | **349** | **349** | **349** |

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account

DCB = Departmental Capital Budget

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **CAPITAL APPROPRIATIONS** |  |  |  |  |  |
| Capital budget - Bill 1 (DCB) | 185 | 190 | 192 | 194 | 195 |
| Equity injections - Bill 2 | - | - | - | - | - |
| **Total capital appropriations** | **185** | **190** | **192** | **194** | **195** |
| **Total new capital appropriations represented by:** |  |  |  |  |  |
| Purchase of non-financial assets | 185 | 190 | 192 | 194 | 195 |
| **Total items** | **185** | **190** | **192** | **194** | **195** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |  |  |  |  |  |
| Funded by capital appropriations  - equity injection (a) | - | - | - | - | - |
| Funded by capital appropriation  - DCB (b) | 185 | 190 | 192 | 194 | 195 |
| Funded internally from departmental resources | - | - | - | - | - |
| **Total acquisitions of non-financial assets** | **185** | **190** | **192** | **194** | **195** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |  |  |  |  |
| Total purchases | 185 | 190 | 192 | 194 | 195 |
| **Total cash used to acquire assets** | **185** | **190** | **192** | **194** | **195** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

(a) Includes both current Bill 2 and prior Act 2, 4, 6 appropriations.

(b) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of departmental asset movements (Budget year 2024–25)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings    $'000** | **Property, plant and equipment  $'000** | **Intangibles    $'000** | **Total    $'000** |
| **As at 1 July 2024** |  |  |  |  |
| Gross book value | - | 4,747 | 38,000 | **42,747** |
| Gross book value - RoU | 23,431 | 707 | - | **24,138** |
| Accumulated depreciation/amortisation and impairment | - | (2,726) | (15,467) | **(18,193)** |
| Accumulated depreciation/amortisation and impairment - RoU | (12,563) | (771) | - | **(13,334)** |
| **Opening net book balance** | **10,868** | **1,957** | **22,533** | **35,358** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| By purchase - appropriation ordinary annual services | - | 190 | - | **190** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **-** | **190** | **-** | **190** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | - | (589) | (2,631) | **(3,220)** |
| Depreciation/amortisation expense - RoU | (2,558) | (12) | - | **(2,570)** |
| Other movements | - | - | - | **-** |
| **Total other movements** | **(2,558)** | **(601)** | **(2,631)** | **(5,790)** |
| **As at 30 June 2025** |  |  |  |  |
| Gross book value | - | 4,937 | 38,000 | **42,937** |
| Gross book value - RoU | 23,431 | 707 | - | **24,138** |
| Accumulated depreciation/amortisation and impairment | - | (3,315) | (18,098) | **(21,413)** |
| Accumulated depreciation/amortisation and impairment - RoU | (15,121) | (783) | - | **(15,904)** |
| **Closing net book balance** | **8,310** | **1,546** | **19,902** | **29,758** |

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use Asset

Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| Grants – MREA | 945,880 | 984,155 | 1,001,508 | 999,772 | 1,030,243 |
| Suppliers | 13,128 | 13,542 | 13,790 | 14,036 | 14,315 |
| **Total expenses administered on behalf of Government** | **959,008** | **997,697** | **1,015,298** | **1,013,808** | **1,044,558** |
| **REVENUES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| Recoveries | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 |
| Sales of goods and services | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 |
| **Total income administered on behalf of Government** | **10,000** | **10,000** | **10,000** | **10,000** | **10,000** |

Prepared on Australian Accounting Standards basis.

MREA = Medical Research Endowment Account

Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| **Financial assets** |  |  |  |  |  |
| Cash and cash equivalents | 304,518 | 270,693 | 240,284 | 230,261 | 209,364 |
| Receivables | 1,045 | 1,045 | 1,045 | 1,045 | 1,045 |
| **Total financial assets** | **305,563** | **271,738** | **241,329** | **231,306** | **210,409** |
| **Non-Financial assets** |  |  |  |  |  |
| Prepayments | 705 | 705 | 705 | 705 | 705 |
| **Total financial assets** | **705** | **705** | **705** | **705** | **705** |
| **Total assets administered on behalf of Government** | **306,268** | **272,443** | **242,034** | **232,011** | **211,114** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| **Payables** |  |  |  |  |  |
| Grants | 5,401 | 5,401 | 5,401 | 5,401 | 5,401 |
| Suppliers | 7,927 | 7,927 | 7,927 | 7,927 | 7,927 |
| Other | 205 | 205 | 205 | 205 | 205 |
| **Total payables** | **13,533** | **13,533** | **13,533** | **13,533** | **13,533** |
| **Total liabilities administered on behalf of Government** | **13,533** | **13,533** | **13,533** | **13,533** | **13,533** |
| Prepared on Australian Accounting Standards basis. | | | | | |

Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2023–24 Estimated actual $'000** | **2024–25 Budget   $'000** | **2025–26 Forward estimate $'000** | **2026–27 Forward estimate $'000** | **2027–28 Forward estimate $'000** |
| **OPERATING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Cash received – other | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 |
| Net GST received | 26,000 | 26,000 | 26,000 | 26,000 | 26,000 |
| **Total cash received** | **36,000** | **36,000** | **36,000** | **36,000** | **36,000** |
| **Cash used** |  |  |  |  |  |
| Grant payments | 945,880 | 984,155 | 1,001,508 | 999,772 | 1,030,243 |
| Suppliers | 13,128 | 13,542 | 13,790 | 14,036 | 14,315 |
| Net GST paid | 26,000 | 26,000 | 26,000 | 26,000 | 26,000 |
| **Total cash used** | **985,008** | **1,023,697** | **1,041,298** | **1,039,808** | **1,070,558** |
| **Net cash from (or used by) operating activities** | **(949,008)** | **(987,697)** | **(1,005,298)** | **(1,003,808)** | **(1,034,558)** |
| **Net increase (or decrease) in cash held** | **(949,008)** | **(987,697)** | **(1,005,298)** | **(1,003,808)** | **(1,034,558)** |
| Cash at beginning of reporting period | 329,746 | 304,518 | 270,693 | 240,284 | 230,261 |
| Cash from the OPA for: |  |  |  |  |  |
| - appropriations | 923,780 | 953,872 | 974,889 | 993,785 | 1,013,661 |
| **Cash at end of reporting period** | **304,518** | **270,693** | **240,284** | **230,261** | **209,364** |

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account

1. For more information about the strategic direction of the NHMRC, refer to the current Corporate Plan, available at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports [↑](#footnote-ref-2)
2. Further details, including a breakdown of research funding awarded, will be published in the NHMRC Annual Report 2023–24. [↑](#footnote-ref-3)
3. This target assesses the distribution of NHMRC grant expenditure and of new grants awarded. [↑](#footnote-ref-4)
4. Further details, including the results of the 2023 Institutional Annual Compliance Report (not yet available) and reviews by the Australian Research Integrity Committee, will be published in the NHMRC Annual Report   
   2023–24. [↑](#footnote-ref-5)